Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| Line 14: | Line 14: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' E-5501, YM-477, AKR-501 |
*'''Brand name:''' Doptelet | *'''Brand name:''' Doptelet | ||
Latest revision as of 13:11, 8 September 2023
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is established
History of changes in FDA indication
- 2018-05-21: Approved for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
History of changes in EMA indication
- 2019-06-20: Initial authorization as Doptelet
- Uncertain date: Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
- Uncertain date: Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Also known as
- Code names: E-5501, YM-477, AKR-501
- Brand name: Doptelet